| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 28.80 | 0.00 (0.00%) | 19.58 - 31.36 | 5.6 thousand (Below Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 28.80 |
| Day's Range | -- - -- |
| Market Cap | 1.9B |
| Avg Volume (10 Day) | 1.0M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.19 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
ViroPharma Receives Orphan Drug Designation For Maribavir In Europe
PR Newswire - Tuesday 06/11/2013 3:30 AM ET
ViroPharma To Participate In Several June Healthcare Investor Conferences
PR Newswire - Friday 05/31/2013 2:00 PM ET
Subgroup Analyses of Pivotal and Open Label Prevention Trials Showed Effectiveness of ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) in Prevention of Angioedema Attacks in Patients with Hereditary Angioedema (HAE) Poorly Controlled on Anabolic Androgens
PR Newswire - Tuesday 05/28/2013 7:30 AM ET
| VPHM | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -27.82% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.23 | |
| LT Debt/Equity | 0.23 | |
| Earnings Yield | -- | |
| Price/Sales | 4.71 |
| Company | Last | Change |
|---|---|---|
| Alnylam Pharmaceuticals Inc | 30.25 | 0.00% |
| Clovis Oncology Inc | 64.55 | 0.00% |
| Aegerion Pharmaceuticals Inc | 62.13 | 0.00% |
| Mannkind Corp | 7.02 | 0.00% |
| Charles River Laboratories International Inc | 42.14 | 0.00% |
Data is delayed by at least 15 min.